The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
It’s a new term for biotech and its investors.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
PD-(L)1 x VEGF bispecifics prove a big draw.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Crunch time approaches for UroGen.